Fast biotech: Gilead hands $200M to com­pu­ta­tion­al wiz Nim­bus as it speeds in­to PhII NASH tri­al

When Nim­bus Ther­a­peu­tics CEO Don Nichol­son struc­tured his $1.2 bil­lion li­cens­ing deal with Gilead $GILD ear­li­er this year, he built it with the Big Biotech’s rep for fo­cus, sci­ence and clin­i­cal speed in mind.

It paid off. Fast.

To­day, Cam­bridge, MA-based Nim­bus is re­veal­ing that it grabbed a $200 mil­lion mile­stone from Gilead for its ear­ly-stage NASH drug, just 6 months af­ter nab­bing a $400 mil­lion up­front pay­ment. The pay­out now gives them $600 mil­lion this year, half of that $1.2 bil­lion deal to­tal that Gilead signed off on.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.